688506 Sichuan Biokin Pharmaceutical
- 177.40
- +4.51+2.61%
Sichuan Biokin Pharmaceutical News
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement on the completion of the BL-B01D1 (EGFR×HER3-ADC) phase III clinical trial for EGFR-sensitive mutant locally advanced or metastatic non-small cell lung cancer that failed EGFR-TKI treatment
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement on the completion of the first clinical trial of BL-M07D1 (HER2-ADC) for locally advanced or metastatic HER2-positive breast cancer
Investor Relations Activity Schedule (May 22, 2024)
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement on the completion of the first patient enrollment in the phase III clinical trial of BL-B01D1 (EGFR×HER3-ADC) for locally advanced, recurrent, or metastatic HR+HER2-breast cancer
SDIC Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
Legal Opinion of Beijing Junhe (Chengdu) Law Firm on the 2023 Annual General Meeting of Shareholders of Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
Announcement of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on participating in the 2023 Science and Technology Innovation Board Biological Products (2) Group Performance Briefing and the 2024 First Quarter Results Briefing
Explanation of relevant matters by Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2023 Annual General Meeting of Shareholders Meeting Materials
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that the injectable BL-B16D1 (dual antibody ADC) program to treat advanced solid tumors obtained an approval letter for phase I clinical trials
Investor Relations Activity Schedule (May 7, 2024)
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that “BL-B01D1+PD-1 monoclonal antibody ± chemotherapy” has obtained approval notices for 7 phase II clinical trials to treat various advanced solid tumors
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2023 Independent Director Debriefing Report (Li Mingyuan)
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2024 First Quarter Report
Announcement of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on applying for comprehensive credit and guarantee from financial institutions in 2024
China Investment Securities Co., Ltd.'s inspection opinions on Sichuan Baili Tianheng Pharmaceutical Co., Ltd. and its subsidiaries applying for comprehensive credit and guarantees from financial institutions in 2024
Summary of the 2023 Annual Report of Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2023 Annual Report
2023 Audit Report and Financial Statement of Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
Analysis
Price Target
No Data
